Scaling Manufacturing Processes Using Single-Use Technologies

RGtimeline - Stock.adobe.com

Since biological drugs first became available, their demand has been increasing—with the biologic market being valued at approximately US$302.63 billion in 2020 and expecting to reach US$509.23 billion by 2026 at a compound annual growth rate of 9.06% (1). With advancements in research and technologies, the diversity of biological drugs available is broad, including monoclonal antibodies (mAbs), prophylactic vaccines, gene therapy viral vectors (mainly lentivirus and adeno-associated virus), cell therapies (e.g., chimeric antigen receptor T-cell therapy and modified stem cells), and oncolytic viruses (e.g., adenoviruses, herpes viruses, and vaccinia virus).

As a result, the bioreactor vendor and contract development and manufacturing organization industries are under pressure to increase production scale. To meet demand, these industries must feasibly scale up while considering safety, manual operator handling, engineering, infrastructure, costs, and finally biological processing itself.

Read the article in the BioPharm International Partnerships for Outsourcing May 2023 eBook.

About the author

Kai Lipinski, PhD, is the chief scientific officer of Vibalogics.

Article details

BioPharm International
eBook: Partnerships for Outsourcing
May 2023
Pages: 18-23

Citation

When referring to this article, please cite it as Lipinski, K. Scaling Manufacturing Processes Using Single-Use Technologies. BioPharm International, Partnerships for Outsourcing eBook May 2023.